 |
| |
 |
| |
 |
| |
 |
| |
 |
| _____________________________________________________________________________________________________________________ © 2005-11 All Rights Reserved. NOD Pharmaceuticals, Inc. |
| Nodlin |
NOD Pharmaceuticals, Inc. is developing the leading product candidates in China via its wholly
owned subsidiary Biolaxy. Nodlin and Nodexen are the leading candidates under development.
owned subsidiary Biolaxy. Nodlin and Nodexen are the leading candidates under development.
Products
Insulin is the standard treatment for diabetic patients and requires multiple daily injection, often for
life. Nodlin is an oral insulin formulation for basal insulin supplementation currently in Phase 1 trial
in China.
life. Nodlin is an oral insulin formulation for basal insulin supplementation currently in Phase 1 trial
in China.
| Product Preclinical | P1 | P2 | P3 | NDA | Market |
| N |
| Nodlin |
| N |
| Nodexen |
| Nodexen |
Exenatide, a GLP-1 agonist for diabetic treatment, requires twice daily injections. Nodexen is oral
exenatide formulation that may reduce side effects, improve efficacy over conventional injections,
and achieve better compliance.
exenatide formulation that may reduce side effects, improve efficacy over conventional injections,
and achieve better compliance.
 |  |  |
-Innovation Delivered